What Is This CEO Doing to Earn $450 Per Hour?

The questions from analysts at the end of a company's conference call typically fall in the softball category. There's often a lot of backslapping when things go well, "Congrats on the great quarter." And when things aren't all right, many analysts tiptoe around the issue, asking necessary questions to understand where things went wrong, but avoiding calling out management as part of the problem.

Call me cynical, but I think there's a clear reason for the buddy-buddy relationship. Analysts work for investment banks that link companies with investors for secondary offerings. If analysts aren't nice, their co-workers on the banking side aren't going to get any business.

The one that got through...
So it was rather refreshing this week when Geron (NASDAQ: GERN  ) let Robert Lawson, an analyst from Catoosa Fund, ask a few questions at the end of its fourth-quarter earnings conference call this week. Presumably without any need for love from Geron's management, Lawson was free to say whatever he wanted.

And, boy, did he let management have it.

First, a little background
If you haven't been following the company, let's get you up to date quickly.

Geron is most famous for being a stem-cell company, but the biotech dropped the program in late 2011. I thought it was a pretty good move considering the program was expensive and risky. The biotech had two cancer drugs that were further along. Dropping the stem-cell program allowed the company to conserve cash and focus on drugs that would get to market quicker.

Unfortunately, they blew up. First, imetelstat failed a phase 2 trial in breast cancer. Then GRN1005 failed a trial testing its activity on brain metastases in patients with breast cancer.

The company cut back spending, laying off much of its workforce. Operating expenses fell 37% in the fourth quarter.

The new plan involves focusing on imetelstat in other types of cancer. A phase 2 trial in a blood cancer called essential thrombocythemia came back positive. The company plans to wait for data from an investigator-sponsored trial in another blood disorder called myelofibrosis expected this year before launching its own trial, a prudent move for a drug that's only batting .500.

Back to our story
So, what's got Lawton's feathers ruffled? Since John Scarlett took over as Geron's CEO and decided to shift directions, shares are down about 40% while the AMEX biotech index is up more than 60%.

GERN Chart

GERN data by YCharts.

Despite the poor performance, Lawton claims that Scarlett made $900,000 last year, including a $300,000 bonus. Assuming 40 hours a week with two weeks of vacation, that's $450 per hour. "I guess, put simply, what are you doing on a daily basis in 2013 to sort of earn your $450 per hour?" Lawton asked on the conference call.

Scarlett pleaded innocent, claiming that he has no control over his pay that's set by "external advisors and consultants" that use the going rate for a biotech CEO as a guide. Of course, his peers have earned their keep, according to the chart above.

Including Scarlett's pay, Geron expects to burn through about $33 million this year. That's a lot of money waiting around for clinical trial data. Geron doesn't plan on running any company-sponsored clinical trials in 2013. If the investigator-sponsored trial comes back positive it'll start planning for the next trial, which won't start until next year.

Is fighting back the best move?
Lawton didn't say, but it seems safe to assume that his Catoosa Fund owns shares of Geron. The question I have is: Why bother fighting back?

If you don't like the burn rate, sell at a loss and move on. Go buy Simon Property or Citigroup or one of the myriad of companies that give shareholders a say on pay. Shareholders of both companies rejected their CEO pay policies last year. Who can blame them. Citigroup's CEO, Vikram Pandit, produced a 90% loss for shareholders over five years.

Or better yet, buy a successful company. Fellow Fool Daniel Miller thinks Alan Mulally is worth every penny Ford  (NYSE: F  ) is paying him. Shareholders might balk at the nearly 1 milllion shares of stock options he was awarded this year, worth about $12 million at today's prices, but he's turned the company from red to black. Geron, by contrast, hasn't had a profitable year in its entire existence.

Not that that being profitable is necessary for driving value. Seattle Genetics (NASDAQ: SGEN  ) is still burning through cash, but investors don't seem to mind, sending shares up 75% over the last year. The company recently launched its blood cancer drug Adcetris and has a pipeline of drugs progressing toward the market; clearly they can see the light at the end of the profit/loss tunnel.

Geron, on the other hand, has lost more than $850 million since it was founded in 1990. With less than $100 million in the bank, it'll almost certainly have do another round of public financing.

Good thing the investment bank analysts are still talking nice.

While Geron's cash burn may worry shareholders, it wasn't the macroeconomic trend Warren Buffett was referring to when he said "this is the tapeworm that's eating at American competitiveness." Find out what the legendary Oracle of Omaha was talking about in our free report: What's Really Eating At America's Competitiveness. You'll also discover an idea to profit as companies work to eradicate this efficiency-sucking tapeworm. Just click here for free, immediate access.


Read/Post Comments (2) | Recommend This Article (4)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On March 16, 2013, at 10:20 AM, mruyog wrote:

    Good one and very appropriate, Mr. Orelli!! Scarlett-HUh and company at Geron have screwed up, no doubt. Yet, both appear to be greedy and have been squeezing $1M per head for personal for salary and benefits from the cash starved company!! I am a shareholder for of the company for more than a few years and wrote last year to the company's IR asking its executives, who are indepenedently wealthy, to voluntarily take a token $1 annually for salary until the company is clearly ready to commercialize its first product.

    No response! And, complete silence for all other questions and sugggestions!! This is typically the experience of all shareholders I know!! We, the shareholders do smell a rat in the intentions of this management. But what can we do? Complaining to SEC has been like talking to deaf ears!! Retail shareholders in this country, known to be world's best democracy, are not well-served and the politicians are lying in bed with those with money and power. It's a real frustration to be shareholder of such a company.

    Twenty plus years and yet no light at the end of the tunnel!! Managements gobbled up our hundreds of millions of dollars of our hard-earned savings and yet have managed to be arrogant - Thanks to the SEC!! Thanks for addressing all that.

  • Report this Comment On March 16, 2013, at 10:57 AM, mruyog wrote:

    And let me add more: After reading the 10K the company just filed, any body can see the management's arrogance - The deal requires BioTime shareholders to approve it but none such right is given to Geron shareholders although it's Geron shareholders' hundreds of millions of dollars that were spent to acquire those assets!! What a fairness!! Gern management doesm't see any need for that!! What an arrogance!! Also, note that these assets have tio be kept intact and maintained until the deal is finalized prior to Sept, 2013, of course, at Geron shareholders' cost!!

    If you also carefully analyze the deal, Geron shareholders get roughly a tenth of what they already invested! Thus. for long-term Geron shareholders, it's virtual a wash of their investment. All this, after Geron shareholders footing a $1M for less than a year's work to Geron's current COB Huh (who was hired originally to find partners for Geron's stem-cell programs!); and, God knows what hefty fee was paid to Stifel Nicolaus whose one of the analysts just gave a SELL recommendation of Geron shares that has caused a massive slide of the share value!!

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2315969, ~/Articles/ArticleHandler.aspx, 9/14/2014 10:34:04 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement